In 74 patients with IPF receiving antifibrotic therapy, sleep quality improved significantly, as the median Pittsburgh Sleep Quality Index score fell from 9 to 6. Patients with idiopathic pulmonary ...

Best practices most often mentioned by amyloidosis stakeholders included patient-centric multidisciplinary care, responsiveness to patients' questions, and timely intake of new patients who are at ...

Dual pathway blockade targets complement-driven pathology in AChR-positive MG, as well as FcRn-mediated pathogenic IgG recycling. Two patients with refractory anti-acetylcholine receptor (AChR) ...

After the enzyme-linked immunosorbent assay was added to the solid phase red cell adherence test, the detection rate of anti-CD36 increased about 15-fold. Platelet antibodies that may lead to fetal ...

The pathogenic role of CD38-expressing plasma cells in FSGS may be linked to the therapeutic effect, given that circulating CD38+ plasma cell counts have been shown to correlate with disease activity.

Regenxbio announced plans to pursue accelerated FDA approval of RGX-202 and prepare for a potential commercial launch in 2027. The pivotal portion of the trial of RGX-202, a gene therapy for Duchenne ...

The adjusted mean change in forced vital capacity at week 52 was –107.1 mL in patients given placebo, –61.2 mL in patients treated with 9 mg of nerandomilast twice a day, and –64.9 mL in patients ...

Recurrent atraumatic vertebral fractures warrant serum tryptase, KIT testing, and biopsy at augmentation. Indolent systemic mastocytosis (SM) should be suspected in patients presenting with atraumatic ...

Patient-reported outcomes reflected strong acceptance, with a median satisfaction score of 8.9 out of 10 on the Self-Injection Assessment Questionnaire. The zilucoplan (Zilbrysq ®) auto-injector ...

The model had an area under the receiver operating characteristic curve of 0.83 in a high-risk subgroup of patients with conditions that mimic ATTR-CM. An artificial intelligence model trained to ...

The risk of ischemic stroke was 5.8% among patients with ATTR-CM and atrial fibrillation using tafamidis compared with 9.4% in patients not using the treatment. Tafamidis treatment was associated with ...